These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25148232)

  • 1. No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy.
    Winhofer Y; Wolf P; Krššák M; Wolfsberger S; Tura A; Pacini G; Gessl A; Raber W; Kukurova IJ; Kautzky-Willer A; Knosp E; Trattnig S; Krebs M; Luger A
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4299-306. PubMed ID: 25148232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced basal ATP synthetic flux of skeletal muscle in patients with previous acromegaly.
    Szendroedi J; Zwettler E; Schmid AI; Chmelik M; Pacini G; Kacerovsky G; Smekal G; Nowotny P; Wagner O; Schnack C; Schernthaner G; Klaushofer K; Roden M
    PLoS One; 2008; 3(12):e3958. PubMed ID: 19093000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly.
    Fellinger P; Wolf P; Pfleger L; Krumpolec P; Krssak M; Klavins K; Wolfsberger S; Micko A; Carey P; Gürtl B; Vila G; Raber W; Fürnsinn C; Scherer T; Trattnig S; Kautzky-Willer A; Krebs M; Winhofer Y
    JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32106111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.
    Reyes-Vidal CM; Mojahed H; Shen W; Jin Z; Arias-Mendoza F; Fernandez JC; Gallagher D; Bruce JN; Post KD; Freda PU
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2946-55. PubMed ID: 26037515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy.
    Møller N; Schmitz O; Jøorgensen JO; Astrup J; Bak JF; Christensen SE; Alberti KG; Weeke J
    J Clin Endocrinol Metab; 1992 May; 74(5):1012-9. PubMed ID: 1569148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Energy metabolism and substrate oxidation in acromegaly.
    O'Sullivan AJ; Kelly JJ; Hoffman DM; Baxter RC; Ho KK
    J Clin Endocrinol Metab; 1995 Feb; 80(2):486-91. PubMed ID: 7852509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly.
    Bredella MA; Schorr M; Dichtel LE; Gerweck AV; Young BJ; Woodmansee WW; Swearingen B; Miller KK
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4218-4225. PubMed ID: 28945897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors.
    Ronchi CL; Varca V; Beck-Peccoz P; Orsi E; Donadio F; Baccarelli A; Giavoli C; Ferrante E; Lania A; Spada A; Arosio M
    J Clin Endocrinol Metab; 2006 Jan; 91(1):121-8. PubMed ID: 16263816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolic profile in active acromegaly is gender-specific.
    Ciresi A; Amato MC; Pivonello R; Nazzari E; Grasso LF; Minuto F; Ferone D; Colao A; Giordano C
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E51-9. PubMed ID: 23162101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly.
    Ueland T; Fougner SL; Godang K; Lekva T; Schurgers LJ; Scholz H; Halvorsen B; Schreiner T; Aukrust P; Bollerslev J
    J Clin Endocrinol Metab; 2010 Jan; 95(1):361-8. PubMed ID: 19880791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery.
    Damjanović SS; Petakov MS; Raicević S; Micić D; Marinković J; Dieguez C; Casanueva FF; Popović V
    J Clin Endocrinol Metab; 2000 Jan; 85(1):147-54. PubMed ID: 10634378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased adrenergic tone in acromegaly: evidence from direct recording of muscle sympathetic nerve activity.
    Seravalle G; Carzaniga C; Attanasio R; Grassi G; Lonati L; Facchini C; Cozzi R; Fatti LM; Montini M; Vitale G; Sciortino G; Damanti S; Brambilla G; Cavagnini F; Mancia G; Scacchi M
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):262-7. PubMed ID: 22233452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients.
    Ciresi A; Amato MC; Pizzolanti G; Giordano Galluzzo C
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2907-15. PubMed ID: 22679062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment.
    Arlien-Søborg MC; Madsen MA; Dal J; Krusenstjerna-Hafstrøm T; Ringgaard S; Skou N; Høgild M; Jørgensen JOL
    Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly.
    Boero L; Manavela M; Meroño T; Maidana P; Gómez Rosso L; Brites F
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):579-85. PubMed ID: 22510144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes.
    Wolf P; Winhofer Y; Krssak M; Smajis S; Harreiter J; Kosi-Trebotic L; Fürnsinn C; Anderwald CH; Baumgartner-Parzer S; Trattnig S; Luger A; Krebs M
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):387-92. PubMed ID: 27118107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved ejection fraction after exercise training in obesity is accompanied by reduced cardiac lipid content.
    Schrauwen-Hinderling VB; Hesselink MK; Meex R; van der Made S; Schär M; Lamb H; Wildberger JE; Glatz J; Snoep G; Kooi ME; Schrauwen P
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1932-8. PubMed ID: 20173015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.